Oncology and Hematology - Prova Education

49-64 of 226

Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
MinuteCE®
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Jennifer Johnson, MD, PhD
0.50 program credits
- Jennifer Johnson, MD, PhD
0.50 program credits
MinuteCE®
Talking Through Treatment: Patient–Clinician Dialogue on Perioperative Immunotherapy in Locally Advanced HNSCC
Jennifer Johnson, MD, PhD; Adam J. Luginbuhl, MD
0.50 credits 5 episodes
- Jennifer Johnson, MD, PhD
- Adam J. Luginbuhl, MD
0.50 credits 5 episodes
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
MinuteCE®
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
MinuteCE®
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
Adam J. Luginbuhl, MD; Jennifer Johnson, MD, PhD
0.50 program credits
- Adam J. Luginbuhl, MD
- Jennifer Johnson, MD, PhD
0.50 program credits
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
CME/CE
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Neeraj Agarwal, MD, FASCO; Rana McKay, MD
0.25 credits
- Neeraj Agarwal, MD, FASCO
- Rana McKay, MD
0.25 credits
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
CME/CE
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Dr. Felip; Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
- Dr. Felip
- Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
The Future of HNSCC: Aligning Teams, Transforming Care
The Future of HNSCC: Aligning Teams, Transforming Care
CME/CE
The Future of HNSCC: Aligning Teams, Transforming Care
Ravindra Uppaluri, MD, PhD; Nancy Lee, MD, FASTRO
0.25 credits
- Ravindra Uppaluri, MD, PhD
- Nancy Lee, MD, FASTRO
0.25 credits
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
CME/CE
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
María-Victoria Mateos, MD, PhD
0.25 credits
- María-Victoria Mateos, MD, PhD
0.25 credits
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CE
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
María-Victoria Mateos, MD, PhD; Luciano Costa, MD, PhD
0.25 credits
- María-Victoria Mateos, MD, PhD
- Luciano Costa, MD, PhD
0.25 credits
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CE
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Kevin J Harrington, PhD, FRCP, FRCR, FRSB; Cristina Rodriguez, MD
0.50 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Cristina Rodriguez, MD
0.50 credits
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
MinuteCE®
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
Eileen M. O'Reilly, MD; Kathryn Arbour
0.75 program credits
- Eileen M. O'Reilly, MD
- Kathryn Arbour
0.75 program credits
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
MinuteCE®
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
Kathryn Arbour; Eileen M. O'Reilly, MD
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
MinuteCE®
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
Kathryn Arbour; Eileen M. O'Reilly, MD
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
Kathryn Arbour
0.75 program credits
- Kathryn Arbour
0.75 program credits
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
MinuteCE®
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
Kathryn Arbour; Eileen M. O'Reilly, MD
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
RAS Across Tumors: Who to Test When
RAS Across Tumors: Who to Test When
MinuteCE®
RAS Across Tumors: Who to Test When
Kathryn Arbour; Eileen M. O'Reilly, MD
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits

4/9